Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,003.00-1.37%ETH$2,254.70-0.65%GOLD$3,963.20-0.16%OIL$96.91+0.47%
Smart Investors Daily
SID Premium
PC

NASDAQ · PCRX

Pacira BioSciences, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$36.39

Up+$0.01 (+0.03%)

Updated Nov 3, 2026, 12:56 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.17B
P/E ratio
38.27
Dividend yield
0.00%
52-week range
$21.16 – $36.67
Volume
737.24K
Avg. volume
635.91K

Price performance · PCRX

PCRX price history

1M range · 0 trading sessions · Daily adjusted prices

PCRX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest PCRX news

The latest Smart Investors Daily articles mentioning PCRX.

Stock researchCompany · Overview

PCRX research

Overview

Company profile and research snapshot.

Company profile

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$27.00
Implied upside
—
Analysts
13
PCRX recent ratings
DateFirmRatingTarget
Oct 9, 2026HC Wainwright & Co.Neutral—
Oct 9, 2026RBC CapitalSector Perform—
Oct 9, 2026Truist SecuritiesHold—
Oct 8, 2026JP MorganNeutral—
Oct 8, 2026JefferiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing

The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling. With coverage now centered on the agreed US$36.50 per share cash acquisition by Viatris and the question of any remaining upside to that deal price, this new target range helps anchor how research desks are talking about potential outcomes. As you read on, you will see how to track this evolving...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By